ArticleCancers2021

Inferior Outcome of Addition of the Aminopeptidase Inhibitor Tosedostat to Standard Intensive Treatment for Elderly Patients with AML and High Risk MDS.

Jeroen Janssen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.